LeMaitre Vascular insider plans sale of 4,322 shares

LeMaitre Vascular insider Bridget A. Ross filed to sell common stock under a Form 144.

Rhea-AI Filing Summary

LeMaitre Vascular insider Bridget A. Ross filed to sell common stock under a Form 144. The planned sale covers 4,322 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $449,241.48, expected on July 29, 2026 and listed on NASDAQ.

The filing states that the shares relate to a stock option exercise. It also notes that 22,850,739 shares of the issuer’s common stock are outstanding. Over the prior three months, Ross sold 5,044 shares of common stock for aggregate proceeds of $560,366.40 on May 7, 2026.

Key Figures

Shares to be sold: 4,322 shares Aggregate market value of planned sale: $449,241.48 Shares outstanding: 22,850,739 shares +3 more

6 metrics

Shares to be sold 4,322 shares Common stock sale planned under Form 144 on 07/29/2026

Aggregate market value of planned sale $449,241.48 Value of 4,322 LMAT common shares to be sold

Shares outstanding 22,850,739 shares Common shares outstanding for LeMaitre Vascular

Prior 3-month shares sold 5,044 shares Common shares sold by Bridget A. Ross on 05/07/2026

Proceeds from prior sale $560,366.40 Aggregate proceeds from 5,044 shares sold on 05/07/2026

Planned sale date 07/29/2026 Expected date for sale of 4,322 shares

Key Terms

Form 144, Stock Option Exercise, aggregate market value, Securities Sold During The Past 3 Months

4 terms

Form 144 regulatory

"insider Bridget A. Ross filed to sell common stock under a Form 144"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Stock Option Exercise financial

"shares relate to a <b>stock option exercise</b>"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

aggregate market value financial

"an aggregate market value of <b>$449,241.48</b>"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Securities Sold During The Past 3 Months regulatory

"listed in the “Securities Sold During The Past 3 Months” section"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LMAT report in this Form 144?

LeMaitre Vascular reported that Bridget A. Ross plans to sell 4,322 shares of common stock, with an aggregate market value of $449,241.48, in a transaction expected on July 29, 2026 through Morgan Stanley Smith Barney LLC.

How many LMAT shares is Bridget A. Ross planning to sell and when?

Bridget A. Ross plans to sell 4,322 shares of LeMaitre Vascular common stock on or about July 29, 2026. The filing lists Morgan Stanley Smith Barney LLC as the broker and NASDAQ as the trading market.

What is the aggregate market value of the LMAT shares to be sold?

The planned sale covers LMAT common stock with an aggregate market value of $449,241.48. This amount is tied to the 4,322 shares to be sold through Morgan Stanley Smith Barney LLC as disclosed in the Form 144 filing.

How many LMAT shares are outstanding according to this filing?

The filing states that 22,850,739 shares of LeMaitre Vascular common stock are outstanding. This figure provides context for the issuer’s total equity base and is separate from the number of shares that Bridget A. Ross plans to sell.

What prior LMAT stock sales by Bridget A. Ross are disclosed?

Over the prior three months, Bridget A. Ross sold 5,044 shares of LeMaitre Vascular common stock on May 7, 2026, receiving $560,366.40 in aggregate proceeds. These historical sales are listed in the “Securities Sold During The Past 3 Months” section.

How were the LMAT shares in the new sale acquired?

The Form 144 describes the planned sale shares as relating to a Stock Option Exercise. The transaction is identified as involving an option exercise by the issuer, followed by a planned cash sale of 4,322 shares of common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 04:08 PM Accepted by SEC EDGAR 07/29/2026 - 04:08 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001698518
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	LEMAITRE VASCULAR, INC.
SEC File Number	001-33092
Address of Issuer	63 SECOND AVENUE BURLINGTON MASSACHUSETTS 01803
Phone	781-221-2266
Name of Person for Whose Account the Securities are To Be Sold	BRIDGET A ROSS
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4322	449241.48	22850739	07/29/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/29/2026	Stock Option Exercise	Issuer			4322	07/29/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
BRIDGET A ROSS 63 Second Avenue Burlington MA 01803	Common	05/07/2026	5044	560366.40

144: Remarks and Signature

Remarks
Date of Notice	07/29/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Bridget A Ross
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)